SMHGF (Simcere Pharmaceutical Group) Beta: N/A (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMHGF Simcere Pharmaceutical Group Ltd SMHGF
94 GF Score
Price $1.49
GF Value $1.26
View Full Analysis

What is Simcere Pharmaceutical Group Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-26), Simcere Pharmaceutical Group's Beta is Not available.

Simcere Pharmaceutical Group  (OTCPK:SMHGF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Simcere Pharmaceutical Group Beta Related Terms

Simcere Pharmaceutical Group Beta Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Beta Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SMHGF
94GF Score
Simcere Pharmaceutical Group Ltd SMHGF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.49 is trading 18.2% above its estimated GF Value™ of $1.26.

Key valuation signals for SMHGF:

  • Beta: N/A
  • GF Value™: $1.26 vs. price of $1.49 (18.2% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for SMHGF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$1.26
GF Value